Elevar Therapeutics Announces Camrelizumab Plus Rivoceranib Significantly Prolonged Overall Survival and Progression-Free Survival Versus Sorafenib in…

Posted: September 8, 2022 at 2:03 am

Top-line findings will be presented Sept. 10 at the annual European Society for Medical Oncology (ESMO) Congress

See more here:
Elevar Therapeutics Announces Camrelizumab Plus Rivoceranib Significantly Prolonged Overall Survival and Progression-Free Survival Versus Sorafenib in...

Related Posts